Yes, blood tests can help distinguish Alzheimer’s disease from Lewy body dementia, but they are not yet definitive on their own. Researchers have identified specific protein markers in the blood—particularly phosphorylated tau variants, amyloid-beta, and emerging Lewy body-specific proteins—that show up differently in each disease. A person presenting with memory loss and confusion might have one condition or the other, and until recently, doctors had no reliable way to tell them apart without a postmortem brain autopsy. Blood tests are changing that, though they work best as part of a larger clinical picture alongside symptoms, imaging, and neurological examination.
The challenge is real. A 72-year-old might be diagnosed with Alzheimer’s when they actually have Lewy body dementia, which causes hallucinations and movement problems alongside cognitive decline. The symptoms overlap enough that misdiagnosis occurs in clinical practice, and the consequences matter: treatments, symptom management, and family planning differ between the two. Blood biomarkers offer the first practical tool to reduce this confusion while the person is still alive.
Table of Contents
- Why Blood Tests Are Needed to Separate Alzheimer’s and Lewy Body Dementia
- Biomarkers That Actually Separate These Diseases
- What Blood Tests Can Currently Detect About Each Disease
- How These Tests Fit Into Real Diagnostic Practice
- Key Limitations and Why Blood Tests Alone Aren’t Enough
- Availability and How to Access Blood Biomarker Testing
- Why Validation Takes Time and What Current Evidence Shows
Why Blood Tests Are Needed to Separate Alzheimer’s and Lewy Body Dementia
Alzheimer’s disease and lewy body dementia are neuropathologically distinct—they involve different abnormal proteins damaging the brain—yet they produce overlapping cognitive symptoms that confuse clinical diagnosis. Alzheimer’s centers on amyloid-beta plaques and tau tangles accumulating in the brain. Lewy body dementia involves alpha-synuclein protein forming Lewy bodies, which can appear alongside Alzheimer’s pathology in some cases, creating a mixed picture that makes symptoms even harder to interpret. Currently, the only definitive diagnosis is autopsy, which obviously comes too late for treatment decisions. Blood tests work because these brain proteins, or their byproducts, leak into the bloodstream as brain cells die.
By measuring specific variants of these proteins in a blood sample, doctors can infer what’s happening in the brain without waiting for neuroimaging or functional tests that are expensive, time-consuming, or require specialist access. A patient presenting to a primary care doctor with cognitive complaints can have blood drawn and sent to a lab, getting actionable information within days or weeks instead of months of specialist visits and uncertain diagnoses. Real-world example: A 68-year-old woman reports seeing shadowy figures in her home and has trouble with executive function—managing bills, following instructions. Her primary care doctor initially suspects depression mixed with early Alzheimer’s. A blood test showing elevated alpha-synuclein and low amyloid-beta patterns suggests Lewy body dementia instead. The family avoids certain medications (like antipsychotics) that can worsen Lewy body symptoms and begins managing the hallucinations differently.
Biomarkers That Actually Separate These Diseases
The key blood biomarkers for Alzheimer’s include phosphorylated tau (particularly p-tau181 and p-tau217), amyloid-beta 42, and total tau. These markers correlate with the characteristic pathology seen on brain autopsies of Alzheimer’s patients. Lewy body dementia, by contrast, shows a different signature: lower amyloid-beta levels, different tau profiles, and elevated alpha-synuclein or its phosphorylated form (p-alpha-synuclein). Neurofilament light chain is elevated in both but tends to be higher in Lewy body disease, reflecting more neurodegeneration. The limitation here is significant: these biomarkers don’t perfectly separate the diseases in every case. Some people have mixed pathology—Alzheimer’s changes plus Lewy bodies—and their blood test results reflect that complexity.
A test showing high p-tau and moderate alpha-synuclein might indicate mixed disease, not a clear diagnosis. Additionally, biomarkers can appear years before symptoms, so a positive test doesn’t always mean symptomatic disease is present. An asymptomatic 60-year-old with elevated amyloid-beta may not develop Alzheimer’s for a decade, if ever, making the clinical meaning ambiguous. Warning: No single biomarker is perfectly sensitive and specific for either disease. P-tau181 is reasonably good at flagging Alzheimer’s pathology, but some Lewy body patients also show elevated p-tau. Conversely, a person with Lewy body dementia might have relatively normal amyloid-beta levels, which could lead to underdiagnosis if a clinician relies too heavily on that marker alone.
What Blood Tests Can Currently Detect About Each Disease
blood tests available now or in late-stage validation include phospho-tau variants (p-tau181, p-tau217, p-tau384), amyloid-beta 42/40 ratio, total tau, and neurofilament light chain. These have been approved by the FDA or are used in research settings and some clinical labs. For Lewy body dementia specifically, phosphorylated alpha-synuclein (p-alpha-synuclein) in blood has emerged as a promising marker, with research showing it correlates with Lewy pathology in the brain. Some labs now offer alpha-synuclein seeding amplification assays, which detect disease-causing alpha-synuclein seeds with high sensitivity. Example: A 75-year-old presents with parkinsonism (stiffness, slow movement), cognitive decline, and sleeping difficulties. His family reports vivid dreams where he acts out the dreams.
Blood tests show elevated p-alpha-synuclein and low amyloid-beta, pointing toward Lewy body dementia with Parkinson-type features. An MRI confirms no stroke and no focal brain atrophy, and the clinical picture solidifies. This patient would not have been diagnosed accurately a few years ago without extensive specialist evaluation and imaging. The sensitivity and specificity of these tests vary. P-tau217 shows roughly 90% sensitivity for Alzheimer’s pathology in research cohorts, but real-world performance in mixed-pathology cases or in people without advanced disease is less impressive. Alpha-synuclein tests are newer and show promise but are not yet standard across all clinical labs.
How These Tests Fit Into Real Diagnostic Practice
Blood tests are best used as one piece of a larger diagnostic evaluation. A doctor doesn’t order a blood biomarker panel in isolation; they combine it with cognitive testing (Mini-Cog, Montreal Cognitive Assessment), neurological examination, brain imaging (MRI to rule out stroke or tumor), and sometimes advanced imaging like PET scans for amyloid or tau. The blood test adds specificity to the clinical impression. If a patient has symptoms consistent with dementia, imaging shows no alternative explanation, and blood biomarkers point toward Lewy body disease, the diagnosis becomes more confident. The tradeoff: Blood tests are cheaper and faster than PET imaging and require no specialist visit.
A primary care doctor can order a simple blood draw. But they’re less detailed than imaging—a PET scan shows exactly where pathology concentrates in the brain, while blood tests only tell you whether pathology is present and sometimes how much. Blood tests are also not sensitive to very early disease; some people in the preclinical stages may have negative biomarkers despite underlying pathology. Comparison: A PET scan for amyloid costs $3,000–$5,000 and requires a radiology appointment; blood tests cost $500–$2,000 and can be done at any lab. However, insurance coverage for blood biomarkers is still patchy, whereas PET is covered for certain clinical scenarios.
Key Limitations and Why Blood Tests Alone Aren’t Enough
Blood biomarkers are not 100% sensitive or specific for either Alzheimer’s or Lewy body dementia. Some cognitively normal older adults have positive biomarkers but never develop dementia during their lifetime. Others have negative biomarkers but develop symptoms, suggesting late-stage or rapidly progressive disease, or alternative pathology not captured by current markers. The tests can also be positive for years before meaningful cognitive symptoms emerge, creating diagnostic uncertainty. Warning: Relying solely on a blood test to diagnose dementia can lead to overdiagnosis of asymptomatic disease or underdiagnosis of symptomatic disease with atypical biomarker profiles.
A person who is cognitively intact but has elevated p-tau isn’t necessarily ill; they may be in a presymptomatic phase of brain pathology. Conversely, an elderly person with clear dementia symptoms but negative blood biomarkers might be dismissed as having another condition when they actually have advanced disease with a different underlying cause (frontotemporal dementia, primary age-related tauopathy, or others). The practical limitation: Most people see a primary care doctor or geriatrician, not a neurologist or dementia specialist. Those specialists know how to interpret borderline or ambiguous biomarker results. A primary care doctor might order a blood test, see a positive result for p-tau, and diagnose Alzheimer’s without proper cognitive assessment, creating unnecessary worry or inappropriate treatment decisions.
Availability and How to Access Blood Biomarker Testing
Blood tests for dementia biomarkers are becoming available through major lab networks in the United States, though coverage is uneven. Companies like Quest Diagnostics and LabCorp offer some panels, and academic medical centers offer research-based testing. Some tests require a specialist order (a neurologist or geriatrician), while others can be ordered by a primary care physician. Insurance coverage varies—Medicare may cover certain tests if ordered with appropriate clinical indication, while private insurance and out-of-pocket costs differ.
Example of access barrier: A 70-year-old in rural Wyoming with mild cognitive changes wants a blood biomarker test. Her primary care doctor is willing to order it but has no lab within 50 miles that processes advanced dementia biomarkers. She would need to travel to a city, pay for the test out of pocket, or wait for her next neurology appointment (3 months away). Meanwhile, someone in a major metropolitan area with access to academic medical centers might get the same test ordered and processed in a week.
Why Validation Takes Time and What Current Evidence Shows
Blood biomarker tests are validated through large prospective studies where researchers follow thousands of people over years, correlating blood test results with actual brain pathology at autopsy or with imaging findings, cognitive trajectories, and clinical diagnoses. This takes a decade or more. Some tests (like p-tau181 and p-tau217) have published validation data from multiple cohorts showing reasonable correlation with Alzheimer’s pathology. Others (particularly alpha-synuclein variants) have strong mechanistic evidence and smaller cohort data but fewer large independent validations.
Current evidence: P-tau217 shows superior performance compared to p-tau181 in some recent studies, with sensitivity around 90% and specificity around 85% for identifying Alzheimer’s pathology in symptomatic patients. Alpha-synuclein seeding amplification assays show 90%+ sensitivity for Lewy body disease in specialized research settings but have less clinical validation data and are not yet widely available. The gap between research validation and routine clinical use remains significant; tests that look promising in academic cohorts sometimes perform differently in community practice where patients are more diverse and have more comorbidities. A concrete fact: The FDA has not yet approved a stand-alone blood test for Lewy body dementia diagnosis, though Alzheimer’s biomarker tests are moving closer to formal approval. This reflects the state of current evidence—more research has gone into Alzheimer’s blood biomarkers because they’ve been pursued longer and have stronger funding behind them.
- —
